COVID-19 and Genitourinary Cancers Videos

The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore

Details
Neal Shore joins Alicia Morgans to discuss his presentation from the American Urologic Association (AUA) annual meeting titled "Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer Patients Who Received Prior Anti androgen Therapy: PostHoc Analysis of ARCHES." This post hoc analysis aimed to evaluate the efficacy of enzalutamide + androgen deprivation therapy (ADT) versus placebo + ADT in...

The Pattern of Metastatic Spread Impact on Efficacy of Enzalutamide - The ARCHES Study Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...

Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak

Details
In this presentation from Dan Petrylak, MD discusses the recent ARCHES study and offers an insightful perspective into radiographic progression-free survival (rPFS), in prostate cancer. The ARCHES study was a randomized phase 3 study of metastatic hormone-sensitive patients, looking at androgen deprivation therapy (ADT) with Enzalutamide, with a concurrent control group given a placebo, while also...

Improved Survival for Men Treated With Enzalutamide Added to Testosterone Suppression Who Present With Distant Metastases Years After Diagnosis of mHSPC Journal Club – Christopher Wallis and Zachary K...

Details
In this Journal Club, Christopher Wallis and Zachary Klaassen highlight a subset analysis from the ENZAMET trial looking at the impact of enzalutamide on survival outcomes in men whose cancer comes back years later after diagnosis. The ENZAMET trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal...

Intensification of Hormonal Therapy for Men With Metachronous Metastatic Hormone-Sensitive Disease – Chris Sweeney

Details
In a conversation with Alicia Morgans on clinical characteristics of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and identifying subsets of patients to improve personalized treatments, Christopher Sweeney shares data from a European Urology publication Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androge...

The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin

Details
Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...

Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin

Details
Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (ENZAMET) - Tanya Dorff

Details
Tanya Dorff and Alicia Morgans discuss the ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer) trial design and key take-home messages based upon the ASCO 2019 plenary presentation by Christopher Sweeney. The investigators hypothesized that adding enzalutamide to first-line therapy would delay the emergence of castration resistance and thereby improve o...

Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney

Details
Chris Sweeney and Alicia Morgans discuss how the academic collaboration for ENZAMET (Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer) became a reality and initiated in November 2014. The ENZAMET study was led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. ENZAMET (ANZUP 1304) is a global collaborative investigator...

ENZAMET Trial - Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer - Christopher Sweeney

Details
Chris Sweeney and Alicia Morgans discuss the interim analysis of the international academic investigator-sponsored, randomized phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer who received the nonsteroidal antiandrogen agent enzalutamide along with standard-of-care treatment were alive after 3 years, compared with 72% of men who received other nonster...
email news signup